Intrathecal Enzyme Replacement Therapy For Patients With Mucopolysaccharidosis Type I (Hurler Syndrome)
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 28 Feb 2017
At a glance
- Drugs Laronidase (Primary)
- Indications Mucopolysaccharidosis I
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 22 Jan 2016 Planned End Date changed from 1 Dec 2016 to 1 Jun 2017 as reported by ClinicalTrials.gov record.
- 22 Jan 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Jun 2016 as reported by ClinicalTrials.gov record.